Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma

D. Ney,J. Carlson,D. Damek,L. Gaspar,B. Kavanagh,B. Kleinschmidt-DeMasters,A. Waziri,K. Lillehei,K. Reddy,Changhu Chen
DOI: https://doi.org/10.1007/s11060-014-1691-z
2015-03-01
Journal of Neuro-Oncology
Abstract:
What problem does this paper attempt to address?